Is Donating Stem Cells Dangerous?

Donating stem cells is not dangerous in the way most people fear, but it is not painless or entirely without risk. Across tens of thousands of tracked donations, fatal outcomes are extraordinarily rare, and serious complications affect well under one percent of donors. The discomfort, though, is real: bone pain, fatigue, headache, and nausea are common in the days surrounding either donation method. Understanding what actually happens to your body during and after donation, and who faces higher odds of a rough experience, makes the decision a more informed one.

Two Donation Methods, Two Sets of Risks

There are two main ways stem cells are collected, and the risk profile differs between them. In a bone marrow harvest, a doctor inserts needles into the back of your pelvic bone while you are under anesthesia and draws out marrow-rich blood. In peripheral blood stem cell (PBSC) collection, you receive injections of a growth-factor drug for several days beforehand, which pushes stem cells out of your marrow and into your bloodstream, where they are filtered out through an IV line in a process similar to blood donation.

Bone marrow donors tend to have a longer recovery. A head-to-head comparison from a national clinical trial found that PBSC donors reached full recovery in a median of one week, compared to about two and a half weeks for bone marrow donors. At one, two, and three weeks after donation, significantly more PBSC donors reported feeling fully recovered. By 24 weeks, all PBSC donors had recovered, while about three percent of bone marrow donors still had not.¹ Bone marrow donors were also more likely to report moderate-to-severe skeletal pain, body symptoms, and fatigue in the first week.²

Peak levels of pain during the actual collection period, however, were roughly similar between the two methods for most donors. The difference shows up afterward: bone marrow donors hurt more at one week and one month post-procedure, while PBSC donors tend to feel better faster.

What Bone Marrow Donors Actually Experience

The primary risk of a bone marrow harvest is tied to anesthesia, not the needle punctures themselves. A review of safety data found that pain at the aspiration site and fatigue are the most common side effects. In a European analysis of nearly 28,000 first-time bone marrow collections performed over twelve years, only one fatal event occurred, a pulmonary embolism, alongside twelve serious adverse events. The most frequent serious events were cardiac.³

Non-life-threatening complications are more common than most people expect. One retrospective study of nearly 280 bone marrow harvests found that about nine percent of donors had minor complications during the procedure, and 21 percent had them afterward. Nausea and vomiting hit about 14 percent of donors overall. Donors who received spinal anesthesia sometimes developed post-spinal headaches. Women had roughly double the rate of postoperative events compared to men.⁴

The choice between general and spinal anesthesia does not dramatically change the overall complication rate, though each has trade-offs. One study found that donors under spinal anesthesia had higher rates of blood-pressure drops during the procedure, while donors under general anesthesia needed more pain medication afterward and vomited more frequently. Spinal anesthesia appears to leave donors more comfortable in the hours after the harvest, which can matter for healthy people who have no medical reason to be in a hospital.⁵

What PBSC Donors Actually Experience

For PBSC donation, the discomfort starts before collection day. You receive daily injections of G-CSF, a growth-factor drug that stimulates your bone marrow to overproduce stem cells and release them into the blood. Nearly all donors feel something from G-CSF. In one trial, 90 percent of donors reported at least one side effect. Bone pain was by far the most common, hitting roughly 70 to 80 percent of donors. Headache affected about a third, and fatigue, nausea, and insomnia were also frequent.⁶ The bone pain tends to be widespread, often described as a deep ache in the lower back, hips, and sternum, and it scales with the dose of G-CSF administered.⁷

A large prospective study of over 2,400 unrelated PBSC donors found that about one in four experienced significant headache, nausea, or citrate-related tingling during the apheresis process itself. Six percent developed grade III or IV side effects, meaning symptoms serious enough to interfere substantially with daily activities or require medical attention, and 0.6 percent experienced events classified as both serious and unexpected. Complete recovery was universal, though, and no late adverse events attributable to donation were identified at follow-up.⁸

Rare but Serious Complications

The complication that gets the most attention in the medical literature is splenic rupture. G-CSF causes the spleen to enlarge as it ramps up cell production, and in extremely rare cases, the spleen can tear. Case reports describe this happening in healthy donors, sometimes requiring emergency surgery to remove the spleen entirely.⁹ The Spanish Donor Registry documented one such case among its tracked donors, where the rupture occurred twelve hours after the final collection session and required splenectomy.¹⁰ These events are genuinely rare, on the order of a handful of reports across many thousands of donations worldwide, but they are serious enough that donors are typically warned about them and advised to avoid contact sports or heavy lifting during the mobilization period.

For bone marrow donation, the most dangerous acute risks are those associated with any procedure requiring anesthesia: allergic reactions, breathing problems, and blood clots. The European data showing one death from pulmonary embolism in nearly 28,000 procedures puts the fatality risk in the single-digit-per-hundred-thousand range.³

Does G-CSF Cause Cancer Later?

This is probably the most common long-term worry for PBSC donors. Because G-CSF pushes bone marrow into overdrive, there has been concern that it could trigger blood cancers like leukemia down the road. The reassuring answer is that large-scale data have not found an increased risk. A systematic review aggregating eight studies that tracked over 40,000 donors across more than 150,000 person-years of follow-up found just three cases of acute myeloid leukemia. That rate was actually lower than what would be expected in a matched general population, though the authors cautioned that some underreporting is likely since donors who develop cancer years later may not report it back to the transplant center.¹¹ Separate long-term follow-up data likewise found that the rate of blood cancers in stem cell donors did not exceed what would be expected in an age- and sex-matched population.¹²

The evidence is not perfect. Follow-up periods in most studies run to about five to ten years, and very long-latency effects remain theoretically possible. But based on the data in hand, the risk is either nonexistent or too small to detect in very large cohorts, which is a meaningful level of safety.

Who Has a Harder Time

Your experience as a donor is not random. Several factors consistently predict who will have more symptoms and a slower recovery. Women are at considerably higher risk of complications across both donation types. In PBSC donation, female donors needed central-line placement more often (17 percent versus four percent for men), had more apheresis-related side effects, and experienced more bone pain.⁸ For bone marrow donation, women were roughly 67 percent more likely to have moderate-to-severe pain and nearly three times more likely to have moderate-to-severe body symptoms.¹³

Age and weight also matter. Donors aged 50 to 60 were more than twice as likely as younger donors to not fully recover to their pre-donation baseline at one year. Obese donors had increased risk of moderate-to-severe pain across both the collection period and the long-term follow-up window. Heavier PBSC donors (over 95 kilograms) had about 50 percent higher odds of significant side effects compared to lighter donors.¹³ These are not reasons to refuse to donate, but they are worth knowing so you can plan adequate recovery time.

Female donors and older donors also report more fatigue during G-CSF mobilization specifically, adding to the overall pattern of certain groups carrying a disproportionate share of the physical burden.¹⁴

The Screening Process That Keeps It Safe

A significant part of the reason donation is as safe as it is comes down to rigorous screening. Before you donate, you go through a medical history review, a physical examination, and laboratory testing to rule out conditions that could make donation risky for you or could transmit disease to the recipient.¹⁵ For unrelated donors in international registries, the criteria are strict: you generally need to be in unrestricted good health. Related donors, those donating for a family member, face somewhat more relaxed criteria since there may be no alternative match. This can create a tension where a family member with a pre-existing condition that would disqualify them from unrelated donation is still asked to donate for a sibling or parent.¹⁶

International bodies like the World Marrow Donor Association have worked to standardize medical suitability assessments across countries, covering everything from acceptable blood-pressure ranges to how to handle donors with autoimmune conditions or prior cancers.¹⁷ That global safety monitoring now spans 30 years of systematic collection and analysis of serious adverse events, giving transplant centers a much clearer picture of what can go wrong and how to prevent it.¹⁸

The Psychological Side

Physical risks get most of the attention, but the emotional toll of donation is real and often underappreciated. A survey of stem cell donors found that nearly 90 percent experienced at least one type of psychological discomfort during the process. Fear and anxiety were the most common, each reported by about 44 percent of donors, followed by stress, depression, and loneliness.¹⁹

For related donors, the stakes feel personal. A qualitative synthesis of donor experiences found that while many people felt satisfaction and pride, some also felt anxious and unduly pressured to donate. Donors became emotionally invested in the recipient’s outcome and experienced deep grief if the transplant ultimately failed.²⁰ Sibling donors whose brother or sister died after transplant went through recognizable grief, sometimes intensified by guilt over whether they could have done more or whether their cells were somehow inadequate.

Unrelated donors face a different version of this. A study of 325 unrelated donors whose recipients died found surprisingly intense emotional reactions, including sadness, grief, and helplessness, despite the fact that they had never met the person. Most donors still said they were glad they donated and would do it again. They also overwhelmingly preferred being told about the recipient’s death rather than being left in the dark.²¹

Children who donate for siblings occupy an especially complicated position. Research shows that pediatric donors experience more psychological distress than their non-donor siblings, navigating feelings they may not fully understand about illness, responsibility, and family dynamics.²² One somewhat counterintuitive finding: even bereaved sibling donors, those whose brother or sister died after transplant, later reported enhanced self-esteem, happiness, and life satisfaction compared to donors whose siblings survived. The experience of having tried to help, even when it did not work, seemed to confer lasting psychological benefits alongside the grief.²³

Newer Drugs That May Change the Experience

G-CSF has been the standard mobilization drug for PBSC donation for decades, but it is not the only option anymore. Plerixafor, a drug originally developed for patients who respond poorly to G-CSF, is being studied as an alternative or addition for healthy donors. In one study of donors who had trouble mobilizing enough stem cells with G-CSF alone, adding plerixafor produced only mild side effects: about a quarter of donors reported diarrhea, headache, dizziness, or nausea the following day, none of which required more than over-the-counter medication.²⁴

A randomized trial testing plerixafor at different doses in healthy donors found no serious drug-related adverse events. Most side effects were mild and self-limiting: injection-site redness, a bloated feeling, occasional nausea, and brief episodes of rapid heartbeat. Symptoms typically appeared within a few hours and resolved without treatment.²⁵ Whether plerixafor will eventually replace G-CSF for standard use in healthy donors is still an open question, but the early safety data are encouraging. A drug that can mobilize stem cells with less bone pain would meaningfully improve the donor experience, given that bone pain is the single most common and most dreaded side effect of the current process.

What Donors Wish They Had Known

Across qualitative studies, certain themes come up repeatedly in donor accounts. Many donors felt the physical side effects were worse than they had been led to expect, not because clinicians lied, but because abstract descriptions of “bone pain” and “fatigue” do not capture what four days of deep-aching bones actually feel like. Others felt the medical system paid careful attention to the recipient but treated donors as an afterthought once collection was complete, a sentiment researchers have termed “feeling neglected.”²⁰ Family donors in particular sometimes felt an unspoken coercion: no one explicitly forced them, but saying no to a dying relative felt impossible.

At the same time, the vast majority of donors express satisfaction with their decision. Even those who had a rough physical experience or who grieved a recipient’s death tend to report that they would donate again. The emotional complexity of the process, pride alongside anxiety, satisfaction alongside grief, is its own kind of risk that no screening test can fully prepare you for, but it is a risk most people ultimately feel was worth taking.

1
PubMed Central. Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Bone Marrow: A Prespecified Analysis from the Phase III BMT CTN Protocol 0201
2
PubMed Central. Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program
3
PubMed. Safety of bone marrow stem cell donation: a review
4
Bone Marrow Transplantation. Comparison of general vs regional anaesthesia for BM harvesting: a retrospective study of anaesthesia-related complications
5
Bone Marrow Transplantation. Safety and efficacy of spinal vs general anaesthesia in bone marrow harvesting
6
PubMed. Treatment of normal individuals with granulocyte-colony-stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells
7
Bone Marrow Transplantation. Peripheral blood stem cell mobilization and apheresis: analysis of adverse events in 94 normal donors
8
PubMed Central. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program
9
PubMed. Spontaneous splenic rupture in a healthy allogeneic donor of peripheral-blood stem cell following the administration of granulocyte colony-stimulating factor (g-csf). A case report and review of the literature
10
Haematologica. Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry
11
Biology of Blood and Marrow Transplantation. G-CSF and Hematopoietic Stem Cell Donation
12
Haematologica. Severe events in donors after allogeneic hematopoietic stem cell donation
13
Haematologica. Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors
14
PubMed. Psychological and physical side effects during G-CSF mobilization in related donors of allo-HCT
15
PubMed Central. Donor Evaluation for Hematopoietic Stem and Progenitor Cell Collection
16
PubMed. Suitability Criteria for Adult Related Donors: A Consensus Statement from the Worldwide Network for Blood and Marrow Transplantation Standing Committee on Donor Issues
17
Bone Marrow Transplantation. Unrelated adult stem cell donor medical suitability: recommendations from the World Marrow Donor Association Clinical Working Group Committee
18
Bone Marrow Transplantation. 30 years of global collaboration in transplantation and cellular therapy: WMDA’s commitment to donor safety, ethical standards, and equitable access
19
PubMed Central. Physical and Psychological Discomfort Experienced by Hematopoietic Stem-Cell Donors
20
PubMed. Motivations, experiences, and perspectives of bone marrow and peripheral blood stem cell donors: thematic synthesis of qualitative studies
21
PubMed Central. Losing the genetic twin: donor grief after unsuccessful unrelated stem cell transplantation
22
PubMed Central. Hematopoietic stem cell donation in children: a review of the sibling donor experience
23
Bone Marrow Transplantation. The effects of bereavement on adult sibling bone marrow donors’ psychological well-being and reactions to donation
24
PubMed Central. Addition of plerixafor in poorly mobilized allogeneic stem cell donors
25
PubMed Central. Effect of high-dose plerixafor on CD34 + cell mobilization in healthy stem cell donors: results of a randomized crossover trial